Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18

Barclays analyst Glen Santangelo has upgraded Phathom Pharmaceuticals (NASDAQ: PHAT) from Equal-Weight to Overweight. The price target for the stock has been raised from $16 to $18.